Building on world-class science, global leadership in clinical studies, and a growing base of sovereign manufacturing intent, Australia is strengthening the path from great science to commercial products made at home.

The country’s decision to regulate AI through existing sector frameworks, rather than a single AI Act, could give its biotech companies a real advantage as they scale into the Oceanic and APAC markets, and globally.

In a recent interview with pharmaphorum’s Nicole R., our co-founder and CEO Alexander Seyf highlights end-to-end data digitisation and integration as decisive in turning R&D into commercial success. It’s the foundation that also lets AI deliver. That’s what we built autoloMATE® to provide.

Read the full conversation here.